Before a promising compound can be tested on people, pre-clinical research has to be conducted in order to guarantee that it is safe and effective for treating a particular disease or symptom. In vitro and in vivo assays, typically used to evaluate efficacy and safety, are time-consuming, expensive and not fully representative of responses in humans.
With the aid of the Therapeutic Performance Mapping System (TPMS) proprietary technology, Anaxomics offers innovative solutions to address these limitations and take our understanding of drugs and diseases to a new level. By applying cutting-edge advances in systems biology, TPMS models in silico the therapeutic profile of pharmacological compounds based on known and predicted targets. In this manner, TPMS provides the following solutions to accelerate discovery and reduce costs: